Document is current
Any future updates will be listed below
-
Authors
Näslund, Erik https://orcid.org/0000-0002-4989-1831
Strandberg, Gunnar https://orcid.org/0000-0003-4959-6389
Karlsson, Jacob https://orcid.org/0000-0003-2277-0092
Franzén, Stephanie https://orcid.org/0000-0002-5003-2508
Frithiof, Robert https://orcid.org/0000-0003-2278-7951
-
Funding
Funding for this research was provided by:
Uppsala University
- License Information
-
More Information
Article History
Received: 16 November 2025
Accepted: 24 July 2026
First Online: 30 July 2026
Declarations
Ethics approval: The Uppsala Animal Ethics Committee, Uppsala, Sweden, approved the study (5.8.18–02325/2019, date of approval 2019–03-29). All animals were treated according to the Swedish Board of Agriculture guidelines and complied with the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (Council of Europe No 123, Strasbourg 1985).
Consent to participate: Not applicable.
Consent for publication: Not applicable.
Competing interests: SF declares a non-financial interest with Sangair AB and Thioredoxin AB. The other authors have nothing to declare.
